Christopher R. Heery

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

Benjamin Boyerinas, Caroline Jochéms, Massimo Fantini et al. · Cancer Immunology Research · 2015 · 456 citations · Full text

Life Sciences, Immunology, Oncology +17

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Julius Strauss, Christopher R. Heery, Jeffrey Schlom et al. · Clinical Cancer Research · 2018 · 415 citations · Full text

Medicine, Oncology, Pharmacology +17

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

Christopher R. Heery, Geraldine O’Sullivan Coyne, Ravi A. Madan et al. · The Lancet Oncology · 2017 · 295 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

James L. Gulley, Michael Borre, Nicholas J. Vogelzang et al. · Journal of Clinical Oncology · 2019 · 278 citations · Full text

Medicine, Immunology, Oncology +17

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Marijo Bilušić, Christopher R. Heery, Julie Collins et al. · Journal for ImmunoTherapy of Cancer · 2019 · 273 citations · Full text

Medicine, Oncology, Pharmacology +17